Testing effectiveness (Phase 2)UnknownNCT04730232
What this trial is testing
Tilelizumab Combined With Nab-Paclitaxel for High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable
Who this might be right for
High-RiskNon-Muscle Invasive Bladder Urothelial Carcinoma
Tianjin Medical University Second Hospital 63